Compare NICE & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NICE | APGE |
|---|---|---|
| Founded | 1986 | 2022 |
| Country | Israel | United States |
| Employees | 9626 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | NICE | APGE |
|---|---|---|
| Price | $101.79 | $134.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $153.46 | $109.67 |
| AVG Volume (30 Days) | 622.2K | ★ 1.1M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.14 | N/A |
| Revenue Next Year | $9.62 | N/A |
| P/E Ratio | $11.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $83.10 | $35.39 |
| 52 Week High | $153.62 | $134.88 |
| Indicator | NICE | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 78.81 |
| Support Level | $96.49 | $134.03 |
| Resistance Level | $106.36 | N/A |
| Average True Range (ATR) | 4.39 | 0.26 |
| MACD | 0.23 | -1.20 |
| Stochastic Oscillator | 80.36 | 72.67 |
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.